

bsm-33051M**[Primary Antibody]****C-erbB-2/HER2 Mouse mAb****BioSS**
ANTIBODIES

www.bioss.com.cn

sales@bioss.com.cn

techsupport@bioss.com.cn

400-901-9800

— DATASHEET —**Host:** Mouse**Isotype:** IgG**Clonality:** Monoclonal**CloneNo.:** 13H9**GeneID:** 2064**SWISS:** P04626**Target:** C-erbB-2/HER2**Immunogen:** Recombinant human HER2 protein: full length.**Purification:** affinity purified by Protein G**Concentration:** 1mg/ml**Storage:** Size : 50ul/100ul/200ul


0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Size : 200ug (PBS only)


0.01M PBS

Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008].

Applications: **WB** (1:500-2000)**IHC-P** (1:200-1000)**IHC-F** (1:200-1000)**IF** (1:200-1000)**Reactivity:** Human**Predicted MW.:** 138 kDa**Subcellular Location:** Cell membrane ,Cytoplasm**Location:** ,Nucleus**— VALIDATION IMAGES —**

25 ug total protein per lane of various lysates (see on figure) probed with C-erbB-2/HER2 monoclonal antibody, unconjugated (bsm-33051M) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.



Paraformaldehyde-fixed, paraffin embedded (Human breast carcinoma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (C-erbB-2/HER2) Monoclonal Antibody, conjugated (bsm-33051M) at 1:800 overnight at 4°C, followed by operating according to SP Kit(Mouse) (sp-0024) instructions and DAB staining.

— SELECTED CITATIONS —

- **[IF=5.115]** Zhou M et al. A Mansonone Derivative Coupled with Monoclonal Antibody 4D5-Modified Chitosan Inhibit

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

AKR1C3 to Treat Castration-Resistant Prostate Cancer. Int J Nanomedicine. 2020 May 1;15:3087-3098. WB,IF ;Mouse. 32431503

- **[IF=2.559]** Pan G et al. SPECT/CT imaging of HER2 expression in colon cancer-bearing nude mice using 125I-Herceptin.(2018) FEMS Microbiol. Lett.Oct 12;504(4):765-770. IF ;Mouse. 30217443
- **[IF=3.197]** Wei Lu. et al. Molecular mechanisms by which targeted muscle reinnervation improves the microenvironment of spinal cord motor neurons and target muscles. NEUROSCI LETT. 2022 Oct;789:136879 WB ;Rat. 36152746